N-(4-bromo-3-methyl-phenyl)-3-nitro-propanamide | 1333341-06-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(4-bromo-3-methyl-phenyl)-3-nitro-propanamide
• 英文别名: N-(4-bromo-3-methylphenyl)-3-nitropropanamide
• CAS: 1333341-06-2
• 化学式: C₁₀H₁₁BrN₂O₃
• 分子量: 287.113
• InChiKey: DIXPICIQZDURFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-硝基丙酸 、 4-溴-3-甲基苯胺 在 N,N'-二环己基碳二亚胺 作用下， 以83%的产率得到N-(4-bromo-3-methyl-phenyl)-3-nitro-propanamide
  参考文献：
  名称：

  Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor

  摘要：

  Various 3-nitropropionamides were synthesized and evaluated for in vitro activities against log and starved phase culture of two mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among 22 compounds, 1-cyclopropyl-7-(3,5-dimethyl-4-(3-nitropropanoyl) piperazin-1-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (22) was found to be the most active compound in vitro with MICs of 0.16 and 0.04 mu M against log-and starved-phase culture of MTB. Compound 22 also showed good enzyme inhibition of MTB ICL with IC50 of 0.10 +/- 0.01 mu M. The docking studies also confirmed the binding potential of the compounds at the ICL active site. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.062

文献信息

• Synthesis of various 3-nitropropionamides as Mycobacterium tuberculosis isocitrate lyase inhibitor
  作者：Dharmarajan Sriram、Perumal Yogeeswari、Swetha Methuku、Devambatla Ravi Kumar Vyas、Palaniappan Senthilkumar、Mallika Alvala、Variam Ullas Jeankumar

  DOI：10.1016/j.bmcl.2011.07.062

  日期：2011.9

  Various 3-nitropropionamides were synthesized and evaluated for in vitro activities against log and starved phase culture of two mycobacterial species and Mycobacterium tuberculosis (MTB) isocitrate lyase (ICL) enzyme inhibition studies. Among 22 compounds, 1-cyclopropyl-7-(3,5-dimethyl-4-(3-nitropropanoyl) piperazin-1-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (22) was found to be the most active compound in vitro with MICs of 0.16 and 0.04 mu M against log-and starved-phase culture of MTB. Compound 22 also showed good enzyme inhibition of MTB ICL with IC50 of 0.10 +/- 0.01 mu M. The docking studies also confirmed the binding potential of the compounds at the ICL active site. (C) 2011 Elsevier Ltd. All rights reserved.